| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
|
Medicine details |
|
| Medicine name | bempedoic acid (Nilemdo®) |
| Formulation | 180 mg film-coated tablet |
| Reference number | 2696 |
| Indication | Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin‑intolerant, or for whom a statin is contraindicated |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/02/2020 |
| NICE guidance | |
| Commercial arrangement | CAA |